Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Siltuximab - EUSA Pharma/Janssen Biotech

Next Previous
Drug Profile

Siltuximab - EUSA Pharma/Janssen Biotech

Alternative Names: Anti-interleukin-6 monoclonal antibody - Centocor; cCLB8; Chimeric anti-interleukin-6 monoclonal antibody - Centocor; CNTO-328; Sylvant

Latest Information Update: 14 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Biotech
  • Developer BeOne Medicines; Centocor; EUSA Pharma; Janssen Biotech; Memorial Sloan-Kettering Cancer Center; Papa Giovanni XXIII Hospital
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant lymph node hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Giant lymph node hyperplasia
  • Phase III SARS-CoV-2 acute respiratory disease
  • Phase II Multiple myeloma
  • No development reported Paraproteinaemia; Smoldering multiple myeloma
  • Discontinued Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 01 Jan 2024 China includes Siltuximab into the latest National Reimbursement Drug List 2024 (NRDL)
  • 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in SARS-COV-2 acute respiratory disease in Italy (IV)
  • 11 Dec 2021 Efficacy data from the phase II in multicentric castleman disease (iMCD) presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top